NSE · SHUKRAPHAR
Shukra Pharmaceuticals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹44 Cr with net profit ₹16 Cr — a 36.22% net margin, versus 63.9% the period before.
Shareholding
As of 2026-09-30
- Promoter51.15%
- Public48.2%
- FII0.44%
- DII0.22%
35,007 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.12× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #11 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,77,632 Cr | 81.81 | 9.65 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹55,016 Cr | 43.91 | 5.15 | 11.57% | 17.48% |
| Ajanta Pharma Limited | ₹41,037 Cr | 32.5 | 8.45 | 25.99% | 20.31% |
| Rubicon Research Limited | ₹27,764 Cr | 85.48 | 19.63 | 22.94% | 15.47% |
| Shilpa Medicare Ltd. | ₹19,392 Cr | 60.64 | 7.04 | 12.05% | 18.05% |
| Caplin Point Laboratories Ltd. | ₹18,157 Cr | 26.35 | 4.65 | 17.66% | 28.91% |
| Eris Lifesciences Limited | ₹18,136 Cr | 24.23 | 4.38 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹14,435 Cr | 25.79 | 4.33 | 16.8% | 16.51% |
| Bliss GVS Pharma Ltd. | ₹7,161 Cr | 44.02 | 5.55 | 12.49% | 15.01% |
| Senores Pharmaceuticals Limited | ₹5,409 Cr | 40.53 | 5.39 | 13.31% | 18.57% |
| Shukra Pharmaceuticals Limited(this company) | ₹3,639 Cr | 82.23 | 29.18 | 37.38% | 39.15% |
AI analysis
AI-generated · google/gemini-2.5-flashShukra Pharmaceuticals Limited has a market capitalization of Rs 1382 Cr. The company reported a profit margin of 38.88% and a Return on Equity (ROE) of 24.55%. The debt-to-equity ratio is 0.06. As of June 30, 2026, promoter holding stands at 50.9582%.
Positives
- +The company has a high profit margin of 38.88%.
- +Return on Equity is 24.55%.
- +Return on Capital Employed is 31.4961%.
- +Debt-to-equity ratio is low at 0.06.
- +Promoter holding of 50.9582% is above 50% as of June 30, 2026.
Negatives
- −The quarterly net profit declined from 20.36 Cr in December 2025 to -1.72 Cr in March 2026.
- −The quarterly revenue decreased from 39.13 Cr in December 2025 to 6.32 Cr in March 2026.
- −The annual net profit decreased from 5.39 Cr in March 2025 to -1.73 Cr in March 2026.
- −No quarterly results have been disclosed since March 2026.
Financial Performance
The company's quarterly revenue was Rs 6.32 Cr in March 2026, a decrease from Rs 39.13 Cr in December 2025. Net profit for March 2026 was -1.72 Cr, down from 20.36 Cr in December 2025. Annual net profit was 5.39 Cr in March 2025, decreasing to -1.73 Cr in March 2026.
Profitability & Returns
Shukra Pharmaceuticals Limited has a profit margin of 38.88%. The Return on Equity (ROE) is 24.55% and Return on Capital Employed (ROCE) is 31.4961%. Earnings per share (EPS) is 0.5.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.06. The book value per share is 2.05. The annual net profit for March 2026 was -1.73 Cr, with EBITDA at 0.63 Cr for the same period.
Ownership & Pledges
Public shareholding is 48.9242%. There are no promoter shares pledged.
Data as of — price: 2026-11-14 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Shukra Pharmaceuticals Limitedshare price & fundamentals